The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or so
The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.
대표청구항▼
1. A dosage form comprising a capsule having a shell with an outer surface and an opposed inner surface, the inner surface defining at least in part a confined space for holding a drug substance, and the outer surface being exposed to a gastro-intestinal environment, the shell being composed of an e
1. A dosage form comprising a capsule having a shell with an outer surface and an opposed inner surface, the inner surface defining at least in part a confined space for holding a drug substance, and the outer surface being exposed to a gastro-intestinal environment, the shell being composed of an extruded and injection molded composition comprising (i) Ammonio methacrylate Copolymer Type A or ammonium methacrylate Copolymer Type B present in an amount of about 10 to about 80% w/w;(ii) at least one dissolution modifying excipient selected from a swellable solid present in an amount of about 20 to about 65% w/w, and wherein the swellable solid is a blend of hydroxypropylcelluloses having differing molecular weights and wherein such blend comprises a low molecular weight hydroxypropylcellulose having a molecular weight of about 80,000 and a high molecular weight hydroxypropyl cellulose selected from a hydroxyproplycellulose having a molecular weight of about 140,000 and a hydroxypropylcellulose having a molecular weight of about 370,000;optionally in combination with a second dissolution modifying excipient selected from the group consisting of aa) disintegrant present in an amount of about 10 to 40%,b) a water soluble filler present in the range of about 5 to about 70% w/w,c) a low molecular weight solute present in the range of about 2.5 to about 70% w/w, andd) non-reducing sugar present in the range of about 2.5 to about 15% w/w;(iii) a lubricant present in an amount of about 5% to about 25% w/w; and(iv) optionally a surfactant present in an amount of 0 to about 10%, a plasticizer present in an amount of 0 to about 10% w/w and/or a processing agent present in an amount of 0 to about 10% w/w. 2. The dosage form according to claim 1 wherein the copolymer is Ammonio methacrylate Copolymer Type A. 3. The dosage form according to claim 2 wherein the copolymer is present in an amount of about 15 to about 50% w/w. 4. The dosage form according to claim 2 wherein the copolymer is present in an amount of about 20 to about 40% w/w. 5. The dosage form according to claim 2 wherein the lubricant is stearyl alcohol present from about 10 to about 15% w/w. 6. The dosage form according to claim 1 wherein the surfactant is present in an amount of less than 2% w/w. 7. The dosage form according to claim 6 wherein the surfactant is sodium dodecyl sulphate or is a block copolymer of ethylene oxide and propylene oxide. 8. The dosage form according to claim 1 wherein the lubricant is stearyl alcohol, glycerol monostearate (GMS), talc, magnesium stearate, silicon dioxide, amorphous silicic acid, or fumed silica; and combinations or mixtures thereof. 9. The dosage form according to claim 8 wherein the lubricant is stearyl alcohol. 10. The dosage form according to claim 9 wherein the stearyl alcohol is present from about 10 to about 15% w/w. 11. The dosage form according to claim 1 wherein the lubricant is stearyl alcohol present from about 10 to about 15% w/w. 12. The dosage form according to claim 1 wherein the swellable solid is composed of a blend of hydroxypropyl cellulose polymers, each having a differing molecular weight, present in a total amount of about 30% to about 80% w/w. 13. The dosage form according to claim 1 wherein the second dissolution modifying excipient is a non-reducing sugar, a low molecular weight solute, or a water soluble filler. 14. The dosage form according to claim 13 wherein the second dissolution modifying excipient is selected from the group consisting of xylitol, mannitol, lactose, starch, and sodium chloride, and combinations or mixtures thereof. 15. The dosage form according to claim 1 wherein the second dissolution modifying excipient is a disintegrant. 16. The dosage form according to claim 15 wherein the disintegrant is selected from the group consisting of sodium starch glycollate, croscarmellose sodium, crospovidone (cross-linked polyvinyl pyrrolidone), copovidone, polyvinyl pyrrolidone; and combinations or mixtures thereof. 17. The dosage form according to claim 1 wherein the plasticizer is triethyl cifrate (TEC), tributyl cifrate, acetyl triethyl citrate (ATEC), acetyl tributyl citrate (ATBC), dibutyl phthalate, dibutyl sebacate (DBS), diethyl phthalate, vinyl pyrrolidone glycol triacetate, polyethylene glycol, polyoxyethylene sorbitan monolaurate, propylene glycol, or castor oil; and combinations or mixtures thereof. 18. The dosage form according to claim 1 wherein the processing agent is talc. 19. The dosage form according to claim 18 wherein the processing agent is present in an amount of about 1 to about 5% w/w. 20. The dosage form according to claim 1 which further comprises an absorption enhancer. 21. The dosage form according to claim 20 wherein the absorption enhancer is chitosan, lecithin, lectin, a sucrose fatty acid ester, Vitamin E-TPGS; and combinations or mixtures thereof. 22. The dosage form according to claim 1 wherein the Ammonio methacrylate Copolymer Type A is present in an amount of about 15 to 50% w/w, the lubricant is stearyl alcohol, and the at least one dissolution modifying excipient is a blend of hydroxypropylcelluloses having differing molecular weights. 23. The dosage form according to claim 22 wherein the blend of hydroxypropyl cellulose polymers comprises a hydroxypropylcellulose having a molecular weight of about 80,000 and a hydroxypropylcellulose having a molecular weight of about 370,000. 24. The dosage form according to claim 12 wherein the blend of hydroxypropyl cellulose is a hydroxypropylcellulose having a molecular weight of about 80,000 and a hydroxypropylcellulose having a molecular weight of about 370,000. 25. The dosage form according to claim 22 wherein the blend of hydroxypropyl cellulose is of equal % w/w. 26. The dosage form according to claim 22 wherein the blend of hydroxypropyl cellulose is about 32% w/w. 27. The dosage form according to claim 22 wherein the hydroxypropyl cellulose is present in an amount of about 50% w/w. 28. The dosage form according to claim 22 which comprises a second dissolution modifying excipient which is a wicking agent. 29. The dosage form according to claim 28 wherein the wicking agent is lactose. 30. The dosage form according to claim 29 wherein the lactose is present in an amount of about 13% w/w. 31. A dosage form comprising at least one subcomponent having a wall portion made from an extruded material comprising a pharmaceutical composition selected from the group consisting of: #Formulations% w/w1.Eudragit RL10025.00Klucel EF31.50Klucel JF31.50Stearyl alcohol12.002.Eudragit RL10021.60Eudragit RS100 2.40Klucel EF32.00Klucel JF32.00Stearyl alcohol 12.00; and3.Eudragit RL100 2.40Eudragit RS10021.60Klucel EF32.00Klucel JF32.00Stearyl alcohol 12.00. 32. A dosage form according to claim 1, in which the capsule shell has a wall with a thickness in the range of about 0.1-0.8 mm.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (107)
Van Herle, Louis; Wittwer, Fritz, Apparatus and method for sealing capsules.
Siol Werner (Darmstadt DEX) Albrecht Klaus (Mainz DEX) Mller Michael (Alsbach-Hahnlein DEX) Koralewski Klaus (Riedstadt DEX), Elastomeric acrylic resins.
Siol Werner (Darmstadt DEX) Albrecht Klaus (Mainz DEX) Mller Michael (Alsbach-Hahnlein DEX) Koralewski Klaus (Riedstadt DEX), Elastomeric arcylic resins.
Wittwer Fritz (Lupsingen CHX) Tomka Ivan (Lenzburg CHX) Bodenmann Hans-Ulrich (Mnchenstein CHX) Raible Thomas (Jona NJ CHX) Gillow Louis S. (Rockaway NJ), Method for forming pharmaceutical capsules from hydrophilic polymers.
Wittwer Fritz (Lupsingen CHX) Tomka Ivan (Lenzburg CHX) Bodenmann Hans-Ulrich (Mnchenstein CHX) Raible Thomas (Jona NJ CHX) Gillow Louis S. (Rockaway NJ), Method for forming pharmaceutical capsules from starch compositions.
Bodenmann Hans U. (Muenchenstein CHX) Van Herle Louis P. (Berchem-Antwerp BEX) Michel Luc Y. (Fegersheim-Ohnheim FRX) Pins Heinrich (Eberbach DEX) Martens Winand H. (Belsele BEX), Method for producing a joined capsule filled with viscous material.
Krull,Harald; Rosenberg,J철rg; Breitenbach,J철rg; Hofmann,J체rgen; Klenz,Rainer; B체hrle,Hans, Method of producing solid shape forms containing an active ingredient.
Wong Patrick S. L. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Eckenhoff James B. (Los Altos CA) Larsen Steven D. (Dublin CA) Huynh Hoa T. (Union City CA), Multi-unit delivery system.
Wong Patrick S.-L. (2030 Cornell St. Palo Alto CA 94306) Theeuwes Felix (1634 Fallen Leaf La. Los Altos CA 94022) Larsen Steven D. (11732 Betlen Dr. Dublin CA 94568), Osmotic device for delayed delivery of agent.
Hatano Harumi,JPX ; Ito Takahiro,JPX ; Ishibashi Takashi,JPX ; Yoshino Hiroyuki,JPX ; Mizobe Masakazu,JPX, Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract.
Goertz Hans-Helmut (Freinsheim DEX) Klimesch Roger G. (Alsbach-Haehnlein DEX) Laemmerhirt Klaus (Boehl-Iggelheim DEX) Lang Siegfried (Ludwigshafen DEX) Sanner Axel (Frankenthal DEX) Spengler Reinhard, Preparation of solid pharmaceutical forms.
Sothmann Gunnar A. (Kirkkonummi FIX) Marttila Esko V. (Helsinki FIX), Process for the preparation of tablets with retarded liberation of the active agent is predetermined.
Vetter Heinz (Rossdorf DEX) Hoess Werner (Heusenstamm DEX) Dutschke Joachim (Bensheim DEX) Schikowsky Hartmut (Darmstadt DEX), Process for the short-time treatment of a plastic melt with a liquid treatment agent and the plastic thus produced.
Atkinson Linda E. (Portola Valley CA) Dunn John T. (Palo Alto CA) Gale Robert M. (Los Altos CA) Rivera David L. (San Jose CA), Segmented device for simultaneous delivery of multiple beneficial agents.
Am Ende, Mary Tanya; Curatolo, William John; Friedman, Hylar Lewis; Friesen, Dwayne Thomas; Herbig, Scott Max; Shankar, Ravi Mysore; West, James Blair, Sertraline salts and sustained-release dosage forms of sertraline.
Rosenberg Joerg,DEX ; Breitenbach Jorg,DEX, The production of active substance compositions in the form of a solid solution of the active substance in a polymer ma.
May Michael (Griesheim DEX) Hoss Werner (Heusenstamm DEX) Markert Gerhard (Ober-Ramstadt DEX) Siol Werner (Darmstadt DEX), Universally compatible pigment dispersants.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.